Science Corporation Lands $400M to Advance Brain-Computer Interface
Science Corporation raised $400M Series D to advance its brain-computer interface technology and expand vision restoration devices.

The big picture: Science Corporation, the medical technology startup founded by former Neuralink president Max Hodak, has closed a $400 million Series D funding round, valuing the company at $3.5 billion.
Why it matters:
- Restoring Vision: Science Corporation’s first product, PRIMA, is an implantable chip designed to help patients with age-related macular degeneration recover vision, already approved in Europe and undergoing trials for Stargardt disease.
- US Market Entry: The new funding will support the company’s efforts to bring PRIMA to the United States via the FDA’s Humanitarian Device Exemption, targeting rare conditions.
- Future of Neurotech: Beyond vision, Science Corporation’s long-term ambition is to develop bio-hybrid sensors that directly connect to the human brain, potentially offering treatments for conditions like Parkinson’s disease.
How it works:
- PRIMA Device: The company’s initial offering is a wearable and implantable chip that aids in vision recovery for specific degenerative eye conditions, currently available in Germany.
- FDA Pathway: Science Corporation is leveraging the FDA’s Humanitarian Device Exemption, a regulatory path for experimental medical technologies treating rare diseases, to enter the US market.
- Bio-Hybrid Sensors: The core of Science Corporation’s future technology involves creating sensors from a combination of cultured neurons and silicon, designed for direct interaction with the human brain.
The catch: Developing implantable brain-computer interfaces is a highly complex and regulated field, requiring extensive clinical trials and navigating significant ethical considerations. While the vision restoration device is a tangible first step, the broader ambition of direct brain connection faces substantial technical and regulatory hurdles, alongside competition from other well-funded neurotechnology ventures.
Key Facts
- Company: Science Corporation
- Amount: $400M
- Round: Series D
- Investors: Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, PLC Neurotech
- Founder: Max Hodak
- Valuation: $3,500,000,000
- Announced: 2026-11-17
- Sector: Neurotechnology, Brain-Computer Interface
AIPressRoom Weekly
Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.